Guidance

Invasive group A streptococcal disease: managing close contacts in community settings

Guidelines for managing close community contacts of cases of invasive group A streptococcal (iGAS) disease, including flow diagrams.

Documents

UK guidelines for the management of contacts of invasive group A streptococcus (iGAS) infection in community settings

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Factsheet 1. Invasive group A streptococcal infection (iGAS)

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Factsheet 2. Invasive group A streptococcal infection (iGAS) – information for people who inject drugs

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This publication is to help health professionals manage cases of invasive group A streptococcal (iGAS) disease.

Risk information for close community contacts of cases of iGAS infection is also available.

Previous guidance was published by Public Health England.

Updates to this page

Published 19 March 2008
Last updated 7 March 2023 + show all updates
  1. Updated information on risk assessment in nurseries, schools and other childcare settings (section 4.1).

  2. Changed to using diagnosis date (definition included) instead of onset date to define close contacts and the 10-day post-exposure period. Clarified actions required within 10 days of exposure and for the 30-day surveillance period, and that actions should be undertaken for both confirmed and probable cases. Added Clarithromycin as a second line choice for chemoprophylaxis.

  3. Corrected algorithm 4.

  4. Updated guidance.

  5. First published.

Sign up for emails or print this page